medigraphic.com

2021, Número 2

<< Anterior Siguiente >>

Cuba y Salud 2021; 16 (2)


Covid-19 y afecciones neurológicas

Lorigados PL, Pavón FN

Idioma: Español
Referencias bibliográficas: 75
Paginas: 87-96
Archivo PDF: 266.52 Kb.


RESUMEN

Introducción: aunque se considera que el SARS-CoV es principalmente una enfermedad respiratoria, existen múltiples evidencias de que el virus puede afectar varios sistemas de órganos incluidos el sistema nervioso central. En la actualidad, ante la presencia del SARS-CoV-2 se revisan y discuten las evidencias de la capacidad neuroinvasiva de este virus y la ocurrencia de trastornos neurológicos asociados al actual coronavirus.
Desarrollo: esta revisión comenta y resume las principales experiencias reportadas sobre la presencia de afecciones del sistema nervioso central relacionadas con la COVID-19. Hace un análisis de las vías de invasión del coronavirus al sistema nervioso central, así como una descripción de la relación de la COVID-19 con las enfermedades neurológicas. Se realizó una búsqueda en las bases de datos electrónicas MEDLINE a través de PubMed y Scopus. Se acotaron las citas revisadas desde diciembre de 2019 hasta agosto de 2020.
Conclusiones: el seguimiento de los pacientes con COVID-19 debe atender la evaluación de los eventos presentados en el sistema nervioso central tanto desde el punto de vista clínico como pronóstico debido a la real presencia de diferentes manifestaciones neurológicas en los pacientes positivos al SARS-CoV-2.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. Journal of the NeurologicalSciences. 2020:116832. https://doi.org/10.1016/j.jns.2020.116832

  2. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients.Journal of medical virology. 2020;92(6):552-5. https://doi.org/10.1002/jmv.25728

  3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9. doi:10.1001/jama.2020.1585

  4. Xu J, Ikezu T. The comorbidity of HIV-associated neurocognitive disorders and Alzheimer’s disease: a foreseeable medical challengein post-HAART era. Journal of Neuroimmune Pharmacology. 2009;4(2):200-12. https://link.springer.com/article/10.1007/s11481-008-9136-0

  5. Katayama Y, Hotta H, Nishimura A, Tatsuno Y, Homma M. Detection of measles virus nucleoprotein mRNA in autopsied brain tissues.Journal of General Virology. 1995;76(12):3201-4. https://doi.org/10.1099/0022-1317-76-12-3201

  6. Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson’s disease. Movement disorders:official journal of the Movement Disorder Society. 1992;7(2):153-8. https://doi.org/10.1002/mds.870070210

  7. Murray RS, Brown B, Brain D, Cabirac GF. Detection of coronavirus RNA and antigen in multiple sclerosis brain. Annals of Neurology:Official Journal of the American Neurological Association and the Child Neurology Society. 1992;31(5):525-33. https://doi.org/10.1002/ana.410310511

  8. Sharma K, Tengsupakul S, Sanchez O, Phaltas R, Maertens P. Guillain–Barré syndrome with unilateral peripheral facial and bulbar palsyin a child: a case report. SAGE open medical case reports. 2019;7:2050313X19838750. https://doi.org/10.1177/2050313X19838750

  9. Algahtani H, Subahi A, Shirah B. Neurological complications of Middle East respiratory syndrome coronavirus: a report of two cases andreview of the literature. Case reports in neurological medicine. 2016;2016. https://doi.org/10.1155/2016/3502683

  10. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 inWuhan, China. JAMA neurology. 2020;77(6):683-90. https://jamanetwork.com/journals/jamaneurology/article-abstract/2764549

  11. Wang H-Y, Li X-L, Yan Z-R, Sun X-P, Han J, Zhang B-W. Potential neurological symptoms of COVID-19. Therapeutic Advances inNeurological Disorders. 2020;13:1756286420917830. https://doi.org/10.1177/1756286420917830

  12. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction,and proposed neurotropic mechanisms. ACS chemical neuroscience. 2020;11(7):995-8. https://doi.org/10.1021/acschemneuro.0c00122

  13. Baig AM, Sanders EC. Potential Neuroinvasive Pathways of SARS‐CoV‐2: Deciphering the Spectrum of Neurological Deficit Seen inCoronavirus Disease 2019 (COVID‐19). Journal of Medical Virology. 2020. https://doi.org/10.1002/jmv.26105

  14. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronaldeath in the absence of encephalitis in mice transgenic for human ACE2. Journal of virology. 2008;82(15):7264-75. https://jvi.asm.org/content/82/15/7264.short

  15. Wilson MP, Jack AS. Coronavirus disease (COVID-19) in neurology and neurosurgery: A scoping review of the early literature. ClinicalNeurology and Neurosurgery. 2020:105866. https://doi.org/10.1016/j.clineuro.2020.105866

  16. Steardo L, Steardo Jr L, Zorec R, Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations ofCOVID‐19. Acta Physiologica. 2020:e13473. https://doi.org/10.1111/apha.13473

  17. Sun T, Guan J. Novel coronavirus and the central nervous system. European Journal of Neurology. 2020. https://doi.org/10.1111/ene.14227

  18. Matías-Guiu J, Gomez-Pinedo U, Montero-Escribano P, Gomez-Iglesias P, Porta-Etessam J, Matias-Guiu J. Should we expect neurologicalsymptoms in the SARS-CoV-2 epidemic? Neurología (English Edition). 2020. https://doi.org/10.1016/j.nrleng.2020.03.002

  19. Hosking MP, Lane TE. The pathogenesis of murine coronavirus infection of the central nervous system. Critical Reviews™ in Immunology. 2010;30(2).

  20. Xu J, Zhong S, Liu J, Li L, Li Y, Wu X, et al. Detection of severe acute respiratory syndrome coronavirus in the brain: potential role ofthe chemokine mig in pathogenesis. Clinical infectious diseases. 2005;41(8):1089-96. https://doi.org/10.1086/444461

  21. Lau K-K, Yu W-C, Chu C-M, Lau S-T, Sheng B, Yuen K-Y. Possible central nervous system infection by SARS coronavirus. Emerginginfectious diseases. 2004;10(2):342. doi: 10.3201/eid1002.030638

  22. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. The American journal of pathology.2007;170(4):1136-47. https://doi.org/10.2353/ajpath.2007.061088

  23. Tang JW, To KF, Lo AW, Sung JJ, Ng H, Chan PK. Quantitative temporal‐spatial distribution of severe acute respiratory syndromeassociatedcoronavirus (SARS‐CoV) in post‐mortem tissues. Journal of medical virology. 2007;79(9):1245-53. https://doi.org/10.1002/jmv.20873

  24. Hamming I, Timens W, Bulthuis M, Lely A, Navis Gv, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARScoronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology: A Journal of the Pathological Society of GreatBritain and Ireland. 2004;203(2):631-7. https://doi.org/10.1002/path.1570

  25. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. European journal of cell biology. 2003;82(2):53-73. https://doi.org/10.1078/0171-9335-00302

  26. Tsai L-K, Hsieh S-T, Chao C-C, Chen Y-C, Lin Y-H, Chang S-C, et al. Neuromuscular disorders in severe acute respiratory syndrome.Archives of neurology. 2004;61(11):1669-73. doi:10.1001/archneur.61.11.1669

  27. Chao C, Tsai L, Chiou Y, Tseng M, Hsieh S, Chang S, et al. Peripheral nerve disease in SARS:: Report of a case. Neurology.2003;61(12):1820-1. https://doi.org/10.1212/01.WNL.0000099171.26943.D0

  28. Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection of coronavirus in the central nervous system of a child with acutedisseminated encephalomyelitis. Pediatrics. 2004;113(1):e73-e6. https://doi.org/10.1542/peds.113.1.e73

  29. Hui DS, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infectious Disease Clinics.2019;33(4):869-89. https://doi.org/10.1016/j.idc.2019.07.001

  30. Desforges M, Le Coupanec A, Brison É, Meessen-Pinard M, Talbot PJ. Neuroinvasive and neurotropic human respiratory coronaviruses:potential neurovirulent agents in humans. Infectious Diseases and Nanomedicine I: Springer; 2014. p. 75-96. https://link.springer.com/chapter/10.1007/978-81-322-1777-0_6

  31. Bohmwald K, Galvez N, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. Frontiers in cellular neuroscience.2018;12:386. https://doi.org/10.3389/fncel.2018.00386

  32. Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system. Cell host & microbe. 2013;13(4):379-93. https://doi.org/10.1016/j.chom.2013.03.010

  33. Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M, et al. Human coronaviruses and other respiratory viruses:underestimated opportunistic pathogens of the central nervous system? Viruses. 2020;12(1):14. https://doi.org/10.3390/v12010014

  34. Hung EC, Chim SS, Chan PK, Tong YK, Ng EK, Chiu RW, et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patientwith severe acute respiratory syndrome. Clinical Chemistry. 2003;49(12):2108. doi: 10.1373/clinchem.2003.025437

  35. Li Y, Li H, Fan R, Wen B, Zhang J, Cao X, et al. Coronavirus infections in the central nervous system and respiratory tract show distinctfeatures in hospitalized children. Intervirology. 2016;59(3):163-9. https://doi.org/10.1159/000453066

  36. Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, et al. Clinical aspects and outcomes of 70 patients with Middle Eastrespiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. International Journal of Infectious Diseases.2014;29:301-6. https://doi.org/10.1016/j.ijid.2014.09.003

  37. Li K, Wohlford-Lenane C, Perlman S, Zhao J, Jewell AK, Reznikov LR, et al. Middle East respiratory syndrome coronavirus causesmultiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. The Journal of infectious diseases.2016;213(5):712-22. https://doi.org/10.1093/infdis/jiv499

  38. Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, et al. Organ distribution of severe acute respiratory syndrome (SARS) associatedcoronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. The Journal of Pathology: AJournal of the Pathological Society of Great Britain and Ireland. 2004;203(2):622-30. https://doi.org/10.1002/path.1560

  39. Baig AM. Updates on what ACS reported: emerging evidences of COVID-19 with nervous system involvement. ACS ChemicalNeuroscience. 2020;11(9):1204-5. https://doi.org/10.1021/acschemneuro.0c00181

  40. Baig AM. Neurological manifestations in COVID‐19 caused by SARS‐CoV‐2. CNS neuroscience & therapeutics. 2020;26(5):499.doi: 10.1111/cns.13372

  41. Baig AM. Designer’s microglia with novel delivery system in neurodegenerative diseases. Medical hypotheses. 2014;83(4):510-2.https://doi.org/10.1016/j.mehy.2014.08.003

  42. Gowrisankar YV, Clark MA. Angiotensin II regulation of angiotensin converting enzymes in spontaneously hypertensive rat primaryastrocyte cultures. Journal of neurochemistry. 2016;138(1):74-85. https://doi.org/10.1111/jnc.13641

  43. Daly JL, Simonetti B, Plagaro CA, Williamson MK, Shoemark DK, Simon-Gracia L, et al. Neuropilin-1 is a host factor for SARS-CoV-2infection. bioRxiv. 2020. https://doi.org/10.1101/2020.06.05.134114

  44. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry andprovides a possible pathway into the central nervous system. bioRxiv. 2020. https://doi.org/10.1101/2020.06.07.137802

  45. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 andTMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020. https://doi.org/10.1016/j.cell.2020.02.052

  46. Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. Journal of Clinical Neuroscience.2020. https://doi.org/10.1016/j.jocn.2020.05.017

  47. Zhao K, Huang J, Dai D, Feng Y, Liu L, Nie S. Acute myelitis after SARS-CoV-2 infection: a case report. MedRxiv. 2020. https://doi.org/10.1101/2020.03.16.20035105

  48. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. NewEngland Journal of Medicine. 2020. https://www.nejm.org/doi/full/10.1056/NEJMc2008597

  49. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19–associated acute hemorrhagic necrotizing encephalopathy:CT and MRI features. Radiology. 2020:201187. https://doi.org/10.1148/radiol.2020201187

  50. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.The lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5

  51. quan Li L, Huang T, qing Wang Y, ping Wang Z, Liang Y, bi Huang T, et al. COVID-19 patients’ clinical characteristics, discharge rate,and fatality rate of meta-analysis. Journal of Medical Virology. 2020;92(6). https://doi.org/10.1002/jmv.25757

  52. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019:retrospective study. Bmj. 2020;368. https://doi.org/10.1136/bmj.m1091

  53. Sharifi-Razavi A, Karimi N, Zarvani A, Cheraghmakani H, Baghbanian SM. Ischemic stroke associated with novel coronavirus 2019: areport of three cases. International Journal of Neuroscience. 2020:1-5. https://doi.org/10.1080/00207454.2020.1782902

  54. Vollono C, Rollo E, Romozzi M, Frisullo G, Servidei S, Borghetti A, et al. Focal status epilepticus as unique clinical feature of COVID-19:A case report. Seizure. 2020. https://doi.org/10.1016/j.seizure.2020.04.009

  55. Sohal S, Mossammat M. COVID-19 Presenting with Seizures. IDCases. 2020:e00782. https://doi.org/10.1016/j.idcr.2020.e00782

  56. Xiang P, Xu X, Gao L, Wang H, Xiong H, Li R. First case of 2019 novel coronavirus disease with encephalitis. ChinaXiv. 2020;202003:00015.

  57. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARSCoronavirus-2. International Journal of Infectious Diseases. 2020. https://doi.org/10.1016/j.ijid.2020.03.062

  58. Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus.2020;12(3). doi: 10.7759/cureus.7352

  59. Xinhua. Beijing hospital confirms nervous system infections by novel coronavirus. 2020.

  60. Huang YH, Jiang D, Huang JT. A Case of COVID-19 Encephalitis. Brain, Behavior, and Immunity. 2020. doi: 10.1016/j.bbi.2020.05.012

  61. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? TheLancet Neurology. 2020;19(5):383-4. https://doi.org/10.1016/S1474-4422(20)30109-5

  62. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: a case report. Journal of Clinical Neuroscience.2020. https://doi.org/10.1016/j.jocn.2020.04.062

  63. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré syndrome associated with SARS-CoV-2. NewEngland Journal of Medicine. 2020. https://www.nejm.org/doi/full/10.1056/NEJMc2009191

  64. Virani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection.IDCases. 2020:e00771. https://doi.org/10.1016/j.idcr.2020.e00771

  65. Coen M, Jeanson G, Almeida LAC, Hübers A, Stierlin F, Najjar I, et al. Guillain-Barré syndrome as a complication of SARS-CoV-2infection. Brain, behavior, and immunity. 2020. doi: 10.1016/j.bbi.2020.04.074

  66. Camdessanche J-P, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E. COVID-19 may induce Guillain-Barré syndrome. Revueneurologique. 2020. doi: 10.1016/j.neurol.2020.04.003

  67. Padroni M, Mastrangelo V, Asioli GM, Pavolucci L, Abu-Rumeileh S, Piscaglia MG, et al. Guillain-Barré syndrome following COVID-19:new infection, old complication? Journal of neurology. 2020:1. https://doi.org/10.1007/s00415-020-09849-6

  68. Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, et al. Guillain-Barré syndrome related to COVID-19 infection.Neurology-Neuroimmunology Neuroinflammation. 2020;7(4). https://doi.org/10.1212/NXI.0000000000000741

  69. Kim J-E, Heo J-H, Kim H-o, Song S-h, Park S-S, Park T-H, et al. Neurological complications during treatment of middle east respiratorysyndrome. Journal of Clinical Neurology. 2017;13(3):227-33. doi: 10.3988/jcn.2017.13.3.227

  70. Rey NL, Wesson DW, Brundin P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases.Neurobiology of disease. 2018;109:226-48. https://doi.org/10.1016/j.nbd.2016.12.013

  71. Tulisiak CT, Mercado G, Peelaerts W, Brundin L, Brundin P. Can infections trigger alpha-synucleinopathies? Progress in molecularbiology and translational science. 168: Elsevier; 2019. p. 299-322. https://doi.org/10.1016/bs.pmbts.2019.06.002

  72. Papa SM, Brundin P, Fung VS, Kang UJ, Burn DJ, Colosimo C, et al. Impact of the COVID-19 pandemic on Parkinson’s disease andmovement disorders. Mov Disord. 2020;6. DOI: 10.1002/mds.28067

  73. Abdennour L, Zeghal C, Dème M, Puybasset L, editors. Interaction cerveau-poumon. Annales francaises d’anesthesie et de reanimation;2012: Elsevier. https://doi.org/10.1016/j.annfar.2012.04.013

  74. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: Asystematic review. Clinical Neurology and Neurosurgery. 2020;194:105921. https://doi.org/10.1016/j.clineuro.2020.105921

  75. Lu L, Xiong W, Liu D, Liu J, Yang D, Li N, et al. New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: Aretrospective multicenter study. Epilepsia. 2020. https://doi.org/10.1111/epi.16524




2020     |     www.medigraphic.com